Every 8-K that Oric Pharmaceuticals, Inc. (ORIC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ORIC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ORIC filings page.
ORIC Pharmaceuticals, Inc. reported financial results and pipeline progress for the quarter ended June 30, 2026. Cash, cash equivalents and investments totaled $387.6 million, including $59.9 million in net proceeds raised under an at-the-market program, which are expected to fund the operating plan into 2H 2028.
For Q2 2026, research and development expenses were $36.3 million versus $30.5 million a year earlier, and general and administrative expenses were $9.0 million versus $8.5 million. Net loss was $41,492 thousand, with net loss per share of $0.38 compared with $0.47 in Q2 2025.
Operationally, ORIC initiated Himalayas-1, a global Phase 3 registrational trial of rinzimetostat in mCRPC, targeting about 600 patients across 25 countries, and entered a collaboration with Bayer, which will supply NUBEQA (darolutamide) at no cost while ORIC retains full rights to rinzimetostat. Enozertinib continues in Phase 1b NSCLC studies, with multiple data readouts anticipated in 2H 2026 and October 2026.
ORIC Pharmaceuticals amended and restated its 2022 Inducement Equity Incentive Plan, effective July 28, 2026, to increase the shares of common stock reserved for issuance under the plan by 1,100,000, to 3,350,000 shares in total, subject to the plan’s adjustment provisions.
The Inducement Plan, adopted without stockholder approval under applicable Nasdaq Listing Rules, permits various equity awards, including options, restricted stock units, restricted stock, stock appreciation rights, performance shares and performance stock units. Awards may be granted only as inducement awards to new employees after a bona fide break in service, or, where permitted, in connection with a merger or acquisition.
ORIC Pharmaceuticals, Inc. reported results of its annual stockholder meeting and an update to its 2020 Equity Incentive Plan. Stockholders approved an amended and restated plan that changes how many shares can be added each year and clarifies limits on incentive stock options.
The plan’s annual “evergreen” increase was reduced from 5% to 4% of outstanding common shares while removing a prior 2,656,500-share annual cap, and it now caps shares issuable via incentive stock options at 10,000,000, subject to the overall share reserve. The amended plan also eliminates the administrator’s ability to run exchange or repricing programs for outstanding awards or allow transfers of awards to third parties.
At the meeting, held on June 18, 2026, stockholders elected two Class III directors, ratified KPMG LLP as auditor for the year ending December 31, 2026, approved executive compensation on an advisory basis, and chose to hold future advisory votes on executive pay every year. Of 103,517,562 shares outstanding as of April 20, 2026, 94,571,281 were represented, reflecting 91.36% participation.
ORIC Pharmaceuticals reported a first quarter 2026 net loss of $35.8 million, or $0.34 per share, as it advanced two oncology programs. The company selected a 400 mg once-daily dose of rinzimetostat with darolutamide for the Himalayas-1 Phase 3 registrational trial in post-abiraterone mCRPC, expected to start in 1H 2026, supported by favorable safety and landmark rPFS data.
ORIC also reported early rinzimetostat data in post-AR inhibitor mCRPC and continued Phase 1b development of enozertinib across multiple NSCLC settings, with several data updates anticipated in 2H 2026. Cash, cash equivalents and investments were $419.7 million as of March 31, 2026, including $59.9 million raised via an ATM program, which ORIC expects will fund operations into 2H 2028.
ORIC Pharmaceuticals reported updated Phase 1b dose optimization data for rinzimetostat (ORIC-944), its PRC2 inhibitor, in metastatic castration-resistant prostate cancer, and is advancing a 400 mg once-daily dose into Phase 3 in combination with darolutamide.
The 400 mg regimen showed strong prostate-specific antigen (PSA) responses in post-abiraterone patients, with 47% achieving PSA50 and 33% achieving confirmed PSA50, alongside broad and deep PSA declines. Safety data across post-abiraterone and broader post-ARPI populations showed most treatment-related adverse events were Grade 1–2, no Grade 5 events, and only 6–11% Grade 3 events at 400 mg, supporting long-term dosing and adherence.
Exposure–response analyses across 113 patients found no correlation between higher exposure and better efficacy, but higher exposure was associated with more toxicity and dose modifications, reinforcing 400 mg as the recommended Phase 3 dose. Early landmark radiographic progression-free survival rates compared favorably to competitor regimens while using a lower-intensity schedule. The company also highlighted a second late-stage candidate, enozertinib (ORIC-114), and reported cash and investments of about $392 million as of December 31, 2025, plus roughly $20 million raised afterward, providing runway into the second half of 2028.
ORIC Pharmaceuticals, Inc. is offering up to $200.0 million of common shares through a renewed at-the-market program under its existing Sales Agreement with Jefferies LLC, supported by a new 2026 prospectus supplement under its automatic shelf registration.
The company previously sold 13,478,432 shares for approximately $139.7 million in gross proceeds under a 2024 prospectus supplement, and no further sales will occur under that earlier supplement. A legal opinion from Wilson Sonsini Goodrich & Rosati related to the new offering is filed as an exhibit.
ORIC Pharmaceuticals reported fourth quarter and full-year 2025 results alongside major clinical progress in prostate and lung cancer. The company ended December 31, 2025 with $392.3 million in cash, cash equivalents and investments and expects this to fund its operating plan into the second half of 2028.
ORIC raised a total of $264 million in 2025 from a private placement and its ATM program, plus an additional $20.0 million afterward. Full-year R&D expenses were $109.8 million and G&A expenses were $33.2 million, leading to a net loss of $129.5 million, or $1.47 per share.
Clinically, rinzimetostat showed promising Phase 1b data in metastatic castration-resistant prostate cancer, with 55% of patients achieving PSA50 responses and 59% achieving ctDNA clearance, supporting plans for a Phase 3 trial in 1H 2026. Enozertinib generated strong systemic and intracranial responses in EGFR exon 20 and EGFR PACC-mutated NSCLC, with first-line data updates expected in the second half of 2026.
ORIC Pharmaceuticals, Inc. provided a program update on its enozertinib (ORIC-114) candidate, presenting recently announced data from its Phase 1b trial. The update was delivered through a presentation included as Exhibit 99.1, giving stakeholders access to the detailed clinical information the company shared on this program.
ORIC Pharmaceuticals furnished an 8-K under Item 7.01 to provide updated ORIC-944 data slides for use in future investor presentations. The materials are included as Exhibit 99.1 and incorporated by reference in the report.
The company states the information in Item 7.01 and Item 9.01 (including Exhibit 99.1) is furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities, nor incorporated into other filings except by specific reference.
ORIC Pharmaceuticals furnished an update on its financials by issuing a press release covering results for the fiscal quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.
The information under Item 2.02 and Item 9.01 (including Exhibit 99.1) is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities, nor incorporated by reference into other filings unless specifically referenced. The report was signed by Dominic Piscitelli, Chief Financial Officer.
ORIC Pharmaceuticals issued a press release reporting results for the quarter ended June 30, 2025 and announced a strategic pipeline prioritization to concentrate resources on its two lead clinical programs, ORIC-944 and ORIC-114. As part of the refocus, the company will eliminate its discovery research group, reducing headcount by approximately 20%.
The company expects a one-time charge of approximately $1.9 million, primarily for termination and healthcare-related benefits, with the workforce reduction substantially complete and the majority of related charges to be recognized in the third quarter of 2025. The company noted these estimates are subject to assumptions and may change.